EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Kedoya Adyaraya Tbk PT (RSGK) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Kedoya Adyaraya Tbk PT IDR 576, price IDR 1,040, upside -44.6%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · ID · ISIN ID1000163009

KA Thin data Sep 24, 2026

Kedoya Adyaraya Tbk PT

RSGK · JK

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value 576.27 IDR · Strongly overvalued (−45%)
!Quality 52/100
!Mixed Growth (revenue 5y +9.7 %/yr)
!Thin margins · 7.3% net margin (TTM)
✓Low debt · generates free cash flow
!Mixed vs. peers (6/13)
!Narrow moat 41/100
!Evidence only low, so the estimate is less certain
!Weak on past: 17 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

1,844 IDR 610.00 IDR Fair Value 576.27 IDR Sep 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 610.00 IDR – 1,844 IDR · fair‑value band 419.07 IDR – 778.28 IDR · the 1,040 IDR price screens above the 576.27 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Kedoya Adyaraya Tbk PT in your weekly email

Every Wednesday you see whether Kedoya Adyaraya Tbk PT is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Kedoya Adyaraya Tbk owns and operates hospitals in Indonesia. It offers facilities, such as inpatient and outpatient services; and healthcare services, and building and operating hospitals. The company was founded in 1990 and is headquartered in Jakarta, Indonesia. PT Kedoya Adyaraya Tbk is a subsidiary of PT Sarana Meditama Metropolitan Tbk.

Stock analysis

Kedoya Adyaraya Tbk PT (RSGK) currently trades at 1,040 IDR, while our model-based Fair Value estimate is 576.27 IDR, implying the stock looks roughly 80.5% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 632.19 IDR per share, and 2 of the 24 models we run sit above the 1,040 IDR price.

Bear case: the Economic Profit group reads lowest at 273.66 IDR, and 22 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: 419.07 IDR (bear) to 778.28 IDR (bull), the price of 1,040 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Kedoya Adyaraya Tbk PT reported revenue of 470B IDR in FY2025 versus 435B IDR in FY2021, a compound +1.9%/yr. Reported net income was 34.5B IDR in FY2025, compounding −10.1%/yr from FY2021.

Key figures

Market cap 967B IDR (≈ $54.0M) · P/E ratio 27.1 · P/S ratio 1.99 · EPS (TTM) 38.32 IDR · Net margin 7.3% · Return on equity 4.3% · Return on assets (EBIT) 5.8% · Operating margin 10.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 70% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −45%, RSGK screens richer than that median.

Fair Value models

Bear 419.07 IDR Fair Value 576.27 IDR Bull 778.28 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (28.14 IDR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 356.57 IDR 534.94 IDR 767.61 IDR 80
Growth DCF 354.73 IDR 517.73 IDR 719.44 IDR 79
Owner Earnings 202.37 IDR 311.75 IDR 454.43 IDR 76
All 24 models by family
DCF Models
FCF DCF 356.57 IDR 534.94 IDR 767.61 IDR 80
Owner Earnings 202.37 IDR 311.75 IDR 454.43 IDR 76
5Y Revenue Exit 381.13 IDR 637.73 IDR 968.83 IDR 71
5Y EBITDA Exit 624.75 IDR 1,106 IDR 1,682 IDR 74
5Y P/E Exit 439.36 IDR 749.74 IDR 1,083 IDR 70
10Y Revenue Exit 353.61 IDR 564.70 IDR 855.14 IDR 66
10Y EBITDA Exit 498.84 IDR 847.08 IDR 1,333 IDR 67
10Y P/E Exit 396.50 IDR 632.19 IDR 931.26 IDR 63
Earnings-Based
Graham-Dodd 252.40 IDR 902.23 IDR 1,215 IDR 64
Lynch FV 212.53 IDR 303.62 IDR 394.71 IDR 61
PEG = 1.0 212.53 IDR 303.62 IDR 394.71 IDR 57
EPV 239.83 IDR 273.66 IDR 301.12 IDR 74
Multiples
P/E Multiple 612.44 IDR 816.58 IDR 1,021 IDR 63
P/S Multiple 473.25 IDR 630.99 IDR 788.74 IDR 58
P/B Multiple 473.25 IDR 630.99 IDR 788.74 IDR 55
EV/EBIT 608.90 IDR 825.90 IDR 1,043 IDR 66
EV/EBITDA 935.17 IDR 1,261 IDR 1,587 IDR 67
EV/Revenue 422.53 IDR 621.66 IDR 820.80 IDR 53
Asset-Based
NCAV (Graham) 445.74 IDR 597.30 IDR 891.49 IDR 54
Growth DCF
Growth DCF 354.73 IDR 517.73 IDR 719.44 IDR 79
Rev-Margin DCF 381.13 IDR 637.21 IDR 942.93 IDR 72
Economic Profit
Residual Income 599.03 IDR 571.16 IDR 452.56 IDR 76
ROIC Compounder 239.83 IDR 273.66 IDR 301.12 IDR 72
Growth Earnings
Growth-Adj P/E 419.07 IDR 598.68 IDR 778.28 IDR 67

Open the full fair value analysis →

Notify me when RSGK reaches fair value

Put RSGK on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 52/100

Of which business quality 53 · Market factors (momentum, volatility) 43

Profitability 30
Margins and returns on capital today
Quality Growth 39
Are margins and returns improving?
Cashflow 57
Earnings quality: real cash, not paper profit
Fin. Strength 82
Balance sheet, leverage, solvency risk
Investment 72
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 38
Price trend over the last 3–12 months (market factor)
52W Momentum 43
Distance to the 52-week high (market factor)
Net Issuance 40
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 80/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.9%
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−19.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−19.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 10%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+26.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about +23.5% a year for the price.

RSGK screens 80% overvalued. Compare with HCA Healthcare, Inc →

Compare Kedoya Adyaraya Tbk PT with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 258 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 52 · Below median
Fair Value upside −44% · Bottom 25%
Profitability
Return on equity (TTM) 4% · Below median
Return on assets 3% · Below median
Net margin (TTM) 7% · Above median
Operating margin (TTM) 11% · Above median
Growth and dividend
Revenue growth 19% · Top 25%
Balance sheet
Debt / equity 0.12× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (TTM) 27.1× · Pricier than median
P/B 1.16× · Cheaper than median
P/S (TTM) 1.96× · Pricier than median
P/FCF 0.0× · Cheapest 25%
EV/EBITDA 10.7× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)97 · sector 28
PAST (return on equity)17 · sector 31
HEALTH (low debt)94 · sector 89
DIVIDEND (yield)0 · sector 43

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $438.12 $592.64 +35%
Fresenius SE FRE €45.57 €34.54 −24%
Dr. Sulaiman Al Habib Medical Services Group 4013 227.50 SAR 109.45 SAR −52%
IHH Healthcare Berhad, an investment holding company, 5225 8.00 MYR 4.87 MYR −39%
Tenet Healthcare Corporation THC $262.06 $399.58 +52%
DaVita Inc DVA $183.72 $255.97 +39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹9,069 ₹2,908 −68%
Fresenius Medical Care AG FME €39.30 €71.28 +81%
Aier Eye Hospital Group 300015 ¥8.07 ¥10.86 +35%
Encompass Health Corporation EHC $122.76 $96.51 −21%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Kedoya Adyaraya Tbk PT Fair Value". https://www.fairvalue-calculator.com/stock/RSGK

Frequently asked questions

Is Kedoya Adyaraya Tbk PT (RSGK) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 576.27 IDR versus a price of 1,040 IDR, about −45% upside (overvalued).
What is the fair value of RSGK?
Our model-based fair value for Kedoya Adyaraya Tbk PT is 576.27 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 1,040 IDR.
What is the quality score of RSGK?
Kedoya Adyaraya Tbk PT has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kedoya Adyaraya Tbk PT (RSGK)?
Our model-based price target is the fair value of 576.27 IDR (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 419.07 IDR, optimistic scenario 778.28 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Kedoya Adyaraya Tbk PT stock forecast for 2026?
Our models put fair value at 576.27 IDR, about −45% upside versus a price of 1,040 IDR (overvalued). Cautious scenario 419.07 IDR, optimistic scenario 778.28 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Kedoya Adyaraya Tbk PT (RSGK)?
Kedoya Adyaraya Tbk PT reported trailing-twelve-month revenue of about 490B IDR (latest available figure, as of Sep 24, 2026).
What growth is priced into Kedoya Adyaraya Tbk PT (RSGK)?
For today's price to be fair in a discounted-cash-flow model, Kedoya Adyaraya Tbk PT would have to grow free cash flow by +26.7 % per year for five years (discount rate 15.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of RSGK use?
Our models discount Kedoya Adyaraya Tbk PT at 15.0 %: a base by market capitalisation (micro), country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Kedoya Adyaraya Tbk PT that is +26.7 % per year a year over ten years, using the same discount rate (15.0 %) and the same formula as our fair value.
How much growth has Kedoya Adyaraya Tbk PT (RSGK) delivered so far?
Over the past 5 years revenue at Kedoya Adyaraya Tbk PT grew +9.8 % a year. The price currently implies +26.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Kedoya Adyaraya Tbk PT (RSGK) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Kedoya Adyaraya Tbk PT (+26.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Kedoya Adyaraya Tbk PT (RSGK)?
The free-cash-flow yield on the price is 4.08 %: that much free cash flow Kedoya Adyaraya Tbk PT produces per unit of market value. When it exceeds the discount rate of our models (15.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Kedoya Adyaraya Tbk PT (RSGK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kedoya Adyaraya Tbk PT it is 576.27 IDR per share (as of Sep 24, 2026), against a price of 1,040 IDR. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Kedoya Adyaraya Tbk PT stock overvalued or undervalued in 2026?
As of Sep 24, 2026, RSGK trades above its calculated fair value: price 1,040 IDR, fair value 576.27 IDR, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RSGK?
No. The price is what the market pays today (1,040 IDR); the fair value is what the company's own numbers justify (576.27 IDR). For Kedoya Adyaraya Tbk PT the two are 463.73 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Kedoya Adyaraya Tbk PT worth?
The market values Kedoya Adyaraya Tbk PT at about 967B IDR (market capitalisation, as of Sep 24, 2026). Per share that is 1,040 IDR; our models calculate a fair value of 576.27 IDR per share.
What do the bullish and bearish scenarios say about RSGK?
Our models span a range for Kedoya Adyaraya Tbk PT: cautious scenario 419.07 IDR, base 576.27 IDR, optimistic 778.28 IDR per share (as of Sep 24, 2026, price 1,040 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RSGK?
Kedoya Adyaraya Tbk PT trades at a price-to-earnings ratio of 27.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 576.27 IDR is built from several models across several years. Other multiples: P/B 1.2, P/S 2.0, EV/EBITDA 10.7.
How solid is the balance sheet of Kedoya Adyaraya Tbk PT (RSGK)?
Balance-sheet figures for Kedoya Adyaraya Tbk PT (as of Sep 24, 2026): return on equity 4.3%, debt of 0.12 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is RSGK from its 52-week high?
Kedoya Adyaraya Tbk PT trades at 1,040 IDR, about 33% below its 52-week high of 1,560 IDR and 70% above the low of 610.00 IDR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 576.27 IDR is for.
Which stocks are comparable to Kedoya Adyaraya Tbk PT?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kedoya Adyaraya Tbk PT stock attractive at the current price?
The data as of Sep 24, 2026: price 1,040 IDR, calculated fair value 576.27 IDR (−45%), Quality Score 52/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RSGK calculated?
We run Kedoya Adyaraya Tbk PT through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 576.27 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Kedoya Adyaraya Tbk PT itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kedoya Adyaraya Tbk PT (RSGK)?
The closing price on Sep 24, 2026 was 1,040 IDR. Our model-based fair value is 576.27 IDR, about −45% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kedoya Adyaraya Tbk PT right now?
The price sits above even our optimistic bull case (778.28 IDR). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (419.07 IDR to 778.28 IDR) leaves room in how you read the outcome.

Key figures of Kedoya Adyaraya Tbk PT

How large is the market capitalisation of Kedoya Adyaraya Tbk PT (RSGK)?
The market capitalisation of Kedoya Adyaraya Tbk PT is 967B IDR (≈ $54.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kedoya Adyaraya Tbk PT (RSGK)?
The price-to-sales ratio of Kedoya Adyaraya Tbk PT is 1.99 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kedoya Adyaraya Tbk PT (RSGK)?
Earnings per share at Kedoya Adyaraya Tbk PT are 38.32 IDR (price ÷ EPS = P/E 27.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Kedoya Adyaraya Tbk PT (RSGK)?
The net margin of Kedoya Adyaraya Tbk PT is 7.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kedoya Adyaraya Tbk PT (RSGK)?
The return on equity (ROE) of Kedoya Adyaraya Tbk PT is 4.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kedoya Adyaraya Tbk PT (RSGK)?
On an EBIT basis the return on assets of Kedoya Adyaraya Tbk PT is 5.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kedoya Adyaraya Tbk PT (RSGK)?
The operating margin of Kedoya Adyaraya Tbk PT is 10.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kedoya Adyaraya Tbk PT (RSGK)?
Revenue at Kedoya Adyaraya Tbk PT is growing +19.4% versus a year earlier (3y avg +9.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kedoya Adyaraya Tbk PT (RSGK)?
Earnings per share at Kedoya Adyaraya Tbk PT are growing +13.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Kedoya Adyaraya Tbk PT (RSGK) hold?
Kedoya Adyaraya Tbk PT holds more cash than debt, 40.4B IDR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Kedoya Adyaraya Tbk PT in the live analysis

One click puts Kedoya Adyaraya Tbk PT on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.